David Planchard - Concepedia

Author

David Planchard

Also Known As

Anthony Canellas, D Planchard, D. Planchard, David Planchard, David Pride, Geneviève Giraudeau, Jean Mendiboure, P DAVID, P David, P R David

983

Publications

50.3K

Citations

H-Index

Concepts

All Affiliations

Institut Gustave Roussy Inserm Université Paris-Saclay Dana-Farber Cancer Institute Centre National de la Recherche Scientifique

About

David Planchard is an author at Institut Gustave Roussy specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	49	120	13.9K
2	Health Sciences	22	33	2K
3	Engineering	2	2	44
4	Public Health	2	2	152
5	Nursing	1	1	20

David Planchard

220

Publications

45.5K

Citations

H-Index

Page 1

	Year	Citations
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, New England Journal of Medicine	2017	5K
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer Scott Antonia, Augusto Villegas, Davey B. Daniel, New England Journal of Medicine	2017	4.4K
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC Scott Antonia, Augusto Villegas, Davey B. Daniel, New England Journal of Medicine	2018	2.7K
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, New England Journal of Medicine	2019	2.7K
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up David Planchard, Sanjay Popat, Keith M. Kerr, Annals of Oncology	2018	2.2K
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim, New England Journal of Medicine	2015	2.1K
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Naiyer A. Rizvi, Julien Mazières, David Planchard, The Lancet Oncology Checkmate 063Single-arm TrialMedicineImmunologyImmune Checkpoint Inhibitor	2015	1.4K
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial David Planchard, Egbert F. Smit, Harry J.M. Groen, The Lancet Oncology MedicinePathologyBronchial NeoplasmCancer TreatmentOncology	2017	1.3K
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer Kathryn C. Arbour, Laura Mezquita, Niamh M. Long, Journal of Clinical Oncology	2018	1K
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer Laura Mezquita, Édouard Auclin, Roberto Ferrara, JAMA Oncology	2018	925

Page 1